Publications by authors named "Oliver Metzing"
Article Synopsis
- Glomerular kidney diseases start slowly, can lead to severe kidney failure, and require early diagnosis for effective treatment.
- The study focused on evaluating protein biomarkers in children to help detect common nephropathies, particularly related to conditions like Alport syndrome.
- Results showed that specific urinary biomarkers, especially collagen type XIII, hyaluronan-binding protein 2, and complement C4-binding protein, may be effective indicators of early kidney injury.
Background: X-linked hypophosphatemia (XLH) is a rare inherited phosphate-wasting disorder associated with bone and dental complications. Health-related quality of life (HRQoL) is reduced in XLH patients on conventional treatment with phosphate supplements and active vitamin D, while information on patients treated with burosumab is rare.
Methods: HRQoL was assessed in 63 pediatric XLH patients participating in a prospective, observational study and patient registry in Germany using the KIDSCREEN-52 survey instrument and standardized qualitative interviews.
Introduction: Alport syndrome (AS) is a hereditary type IV collagen disease. It starts shortly after birth, without clinical symptoms, and progresses to end-stage kidney disease early in life. The earlier therapy starts, the more effectively end-stage kidney disease can be delayed.
View Article and Find Full Text PDFContext: Burosumab has been approved for the treatment of children and adults with X-linked hypophosphatemia (XLH). Real-world data and evidence for its efficacy in adolescents are lacking.
Objective: To assess the effects of 12 months of burosumab treatment on mineral metabolism in children (aged <12 years) and adolescents (aged 12-18 years) with XLH.